Cypherpunk Technologies Inc. (CYPH)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20262 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cypherpunk Technologies Inc.’s names, not what it holds today.
1 published
3 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Jun 3, 2025 | 12,319,730 | Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody | Pharmaceuticals | Leap Therapeutics, Inc. |
| Mar 8, 2022 | 11,267,876 | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | Pharmaceuticals | Leap Therapeutics, Inc. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| May 2, 2024 | 2024/0141023 | METHODS OF TREATING CANCER USING DKK-1 INHIBITORS | Pharmaceuticals | Leap Therapeutics, Inc. |
| Dec 1, 2022 | 2022/0381786 | USE OF DKK-1 INHIBITORS FOR TREATING CANCER | Pharmaceuticals | Leap Therapeutics, Inc. |
| Sep 15, 2022 | 2022/0289831 | USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODY | Pharmaceuticals | Leap Therapeutics, Inc. · patent 12,319,730 granted from it |
| Sep 19, 2019 | 2019/0284264 | USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODY | Pharmaceuticals | Leap Therapeutics, Inc. · patent 11,267,876 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.